In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. salesforce.com, inc. (CRM) Add to watchlist.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the size or terms of the proposed offering.
Hearsay, which makes compliant communications tools for these types of companies, announced a new partnership with Salesforce today, enabling smooth integration with Salesforce CRM and marketing automation tools. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing its lead product Defencath™ in the U.S. as a catheter lock solution with an initial indication for use of preventing catheter-related bloodstream infections in patients with end-stage renal disease who are receiving hemodialysis via a central venous catheter.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties.
Salesforce Ventures also took on a minority stake in Hearsay.Financial services companies like banks and insurance tend to be heavily regulated. Sehen Sie den täglichen, wöchentlichen oder monatlichen Verlauf ab der Ausgabe der Aktien von Salesforce.com Inc.
Yahoo Finance DocuSign CEO: Shift to digital accelerated by COVID-19 pandemic DocuSign CEO Dan Springer tells Yahoo Finance the work from home trend is here to stay. Yahoo Finanzen bietet Ihnen kostenlose Aktienkurse, topaktuelle Nachrichten, Portfolio-Management-Ressourcen, internationale Marktdaten, soziale Interaktion und Hypothekensätze, damit Sie Ihre Finanzen besser verwalten können.
Currency in USD
190,13-0,83 (-0,43%) Ab 3:31PM EDT.
NYSE - NYSE Delayed Price.
He's Now Helping Others By Sharing His Top Picks.CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.Discover new investment ideas by accessing unbiased, in-depth investment researchNYSE American - NYSE American Delayed Price. Hearsay, which makes compliant communications tools for these types of companies, announced a new partnership with Salesforce today, enabling smooth integration with Salesforce CRM and marketing automation tools.
Find the latest CorMedix Inc. (CRMD) stock quote, history, news and other vital information to help you with your stock trading and investing. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.Investor Contact:Dan Ferry Managing Director LifeSci Advisors 617-430-7576Jeff Bishop Went From Rags To Riches And Made Millions Trading Stocks And Options From Home.
Währung in USD. Auf Yahoo Finanzen sehen Sie den Kursverlauf der Aktien von CRM. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: risks related to the timing of and our ability to obtain FDA approval of the New Drug Application for Defencath™; relying on preclinical results that may not be indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; the risks and uncertainties associated with research for additional uses for taurolidine; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on current, planned or future research, including the continued development of Defencath™/Neutrolin® and research for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; and the ability to retain and hire necessary personnel to staff our operations appropriately. Find the latest Salesforce.com Inc (CRM) stock quote, history, news and other vital information to help you with your stock trading and investing. The Company plans to use the net proceeds for general corporate purposes, including obtaining regulatory approval and commercialization of Defencath™ in the U.S., research and development, and working capital and capital expenditures.SunTrust Robinson Humphrey and JMP Securities are acting as joint book-running managers for the offering.The securities described above are being offered pursuant to a “shelf” registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). Currency in USD